• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

    3.185 -0.135 (-4.07%)
    Streaming Delayed Price Updated: 1:47 PM EDT, Aug 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 542,389
    Open 3.290
    Bid (Size) 3.180 (2,400)
    Ask (Size) 3.190 (2,700)
    Prev. Close 3.320
    Today's Range 3.180 - 3.320
    52wk Range 1.350 - 4.600
    Shares Outstanding 22,506,956
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
    From Natera, Inc.
    Via Business Wire

    Performance

    YTD
    +96.6%
    +96.6%
    1 Month
    -6.3%
    -6.3%
    3 Month
    -17.7%
    -17.7%
    6 Month
    +31.6%
    +31.6%
    1 Year
    +23.4%
    +23.4%

    More News

    Read More
    News headline image
    Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart ↗
    Via Chartmill
    News headline image
    Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Tuesday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
    Via MarketMinute
    Topics Initial Public Offering Intellectual Property Regulatory Compliance
    News headline image
    Top movers in Wednesday's pre-market session ↗
    Via Chartmill
    News headline image
    Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?
    Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market
    What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?
    The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 3.185
    When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 08/28/26 01:47 PM ET
    What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 71.68M
    How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?
    Eledon Pharmaceuticals, Inc. - Common Stock has 72M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.